Preserving vision with verteporfin photodynamic therapy

Hospital Medicine

Volumn 65, Issue 1, 2004, Pages 39-43

  Yang, Yit Chiun ^a  

^a Wolverhampton Eye Infirmary   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT; PORPHYRIN;

DRUG SAFETY; HUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; RETINA MACULA DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISION; VISUAL DISORDER; VISUAL IMPAIRMENT; ALGORITHM; CLINICAL TRIAL; METHODOLOGY; MULTICENTER STUDY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; VISUAL ACUITY;

ALGORITHMS; CLINICAL TRIALS; HUMANS; MACULAR DEGENERATION; MULTICENTER STUDIES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; VISION DISORDERS; VISUAL ACUITY;

EID: 1542377994     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2004.65.1.2417     Document Type: Review

References (30)

1. Allison BA, Pritchard PH, Levy JG (1994) Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer 69: 833-9
2. Bressler NM, Gills JP (2000) Age-related macular degeneration. Br Med J 321: 1425-7
3. Bressler SB, Bressler NM, Fine SL et al (1982) Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 93: 157-63
4. Bressler NM, Bressler SB, Fine SL (1988) Age-related macular degeneration. Surv Ophthalmol 32: 375-413
5. Diabetes Control and Complications Trial Research Group (1995) The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 122: 561-8
6. Dougherty TJ, Gomer CJ, Henderson BW et al (1998) Photodynamic therapy. J Natl Cancer Inst 90: 889-905
7. Early Treatment Diabetic Retinopathy Study Research Group (1987) Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report no. 4. Int Ophthalmol Clin 27(4): 265-72
8. Evans J, Wormald R (1996) Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol 80: 9-14
9. Gaffney J, West D, Arnold F, Sattar A, Kumar S (1985) Differences in the uptake of modified low density lipoproteins by tissue cultured endothelial cells. J Cell Sci 79: 317-25
10. Harding S (2001) Photodynamic therapy in the treatment of subfoveal choroidal neovascularisation. Eye 15: 407-12
11. Medical Research Council Working Party (MRC) (1985) MRC trial of treatment of mild hypertension: principal results. Br Med J 291: 97-104
12. National Institute for Clinical Excellence (2003) Guidance on the use of Photodynamic Therapy for Age-related Macular Degeneration. Technology Appraisal Guidance 68. National Institute for Clinical Excellence, London
13. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR (2003) How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom. Br J Ophthalmol 87: 312-17
14. Owsley C, Sloane ME (1987) Contrast sensitivity, acuity and the perception of 'real-world' targets. Br J Ophthalmol 71: 791-6
15. Rubin GS, Roche KB, Prasada-Rao P, Fried LP (1994) Visual impairment and disability in older adults. Optom Vis Sci 71: 750-60
16. Rubin GS, Bressler NM (2002) The Treatment of Age-Related Macular Degeneration with Photodynamic therapy (TAP) study group. Effects of verteporfin therapy on contrast sensitivity: results from the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) investigation-TAP report No 4. Retina 22: 536-44
17. Saperstein DA, Rosenfeld PJ, Bressler NM et al (2002) Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology 109: 1499-505
18. Schmidt-Erfurth U, Hasan T (2000) Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 45: 195-214
19. Schmidt-Erfurth U, Bauman W, Gragoudas E et al (1994a) Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 101: 89-99
20. Schmidt-Erfurth U, Hasan T, Gragoudas E et al (1994b) Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 101: 1953-61
21. Schmidt-Erfurth U, Hasan T, Schomacker K, Flotte T, Birngruber R (1995) In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med 17: 178-88
22. Sharma S (2001) Update in retina: photodynamic therapy for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Can J Ophthalmol 36: 7-10
23. Talks SJ, Yang YC, Gee L, Harding SP (2003) Visual acuity outcomes from photodynamic therapy: report number two from the PDT users group surveillance programme. Paper presented at the annual congress of the Royal College of Ophthalmologists, 20-22 May 2003, Birmingham, UK
24. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol 117: 1329-45
25. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 119: 198-207
26. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2002) Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 5. Arch Ophthalmol 120: 1307-14
27. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups (2003a) Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP Report No 2. Arch Ophthalmol 121: 1253-68
28. Treat ment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups (2003b) Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration - TAP and VIP report No. 1. Am J Ophthalmol 136: 407-18
29. Verteporfin In Photodynamic Therapy (VIP) Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin In Photodynamic Therapy Report 2. Am J Ophthalmol 131: 541-60
30. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, and Verteporfin In Photodynamic Therapy (VIP) Study Group Principal Investigators (2002) Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22: 6-18